<DOC>
	<DOC>NCT02488629</DOC>
	<brief_summary>To evaluate the safety and efficacy of SCB01A in head and neck cancer.</brief_summary>
	<brief_title>Study of SCB01A in Patient With Head and Neck Cancer</brief_title>
	<detailed_description>The study is designed to evaluate the safety and efficacy of SCB01A in patients with recurrent or metastatic squamous cell carcinoma in head and neck.</detailed_description>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>1. Confirmed squamous cell carcinoma of head and neck 2. Patients with nonresectable, unfeasible radiotherapy, recurrent or metastatic carcinoma, after previous treatment with platinum agent. 3. At least one measurable tumor lesion according to RECIST 4. Suitable Eastern Cooperative Oncology Group (ECOG) performance status 5. All eligible patients of childbearing potential have to use effective contraception 6. Signed informed consent before enrolment 1. Receiving Chemotherapy, radiation therapy, major surgery or investigational agents 2. Severe pulmonary obstructive or restrictive disease 3. Uncontrolled inflammatory disease 4. Clinically significant cardiac disease 5. Results of laboratory tests 6. Pregnancy or nursing status 7. Known hypersensitivity to any component of SCB01A 8. History of exposure to SCB01A or its analogues 9. History of malignancy other than head and neck cancer 10. History of active or significant neurological disorder or psychiatric disorder 11. Any other reason the investigator deems the patient to be unsuitable for the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Head and neck squamous cell carcinoma</keyword>
</DOC>